To include your compound in the COVID-19 Resource Center, submit it here.

ALD518: Phase IIb started

Bristol-Myers began a double-blind, placebo-controlled, international Phase IIb trial to evaluate subcutaneous 25, 100 or 200 mg

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE